Tirzepatide (Mounjaro, Eli Lilly) is indicated for 'the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
in addition to other medicinal products for the treatment of diabetes'.
The dosage schedule is available in the summary of product characteristics for tirzepatide.
The list prices of tirzepatide (excluding VAT; company communication) for a 4-week supply of pre-filled pen devices for subcutaneous injection are:
£133.00 for 2.5 mg
£180.00 for 5 mg
£255.00 for 7.5 mg and 10 mg
£330.00 for 12.5 mg and 15 mg.
The company has a commercial arrangement. This makes tirzepatide available to the NHS at a cost-effective price determined by NICE. The details of this arrangement are commercial in confidence.